Novel Combinations for the Treatment of Metastatic Breast Cancer

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

(2017) D. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic breast cancer (MBC): FDA approval overview

(2017) P. Cortazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05)

(2017) G. Von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer

(2017) H. H. Roché et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy

(2017) L. T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)

(2017) S. Gluck et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer

(2017) A. Tutt et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer.

(2010) SM Tolaney et al.   CANCER RESEARCH

Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab.

(2010) J Baselga et al.   CANCER RESEARCH

Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+ metastatic breast cancer (MBC).

(2010) A Jagiello-Gruszfeld et al.   CANCER RESEARCH

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results.

(2010) E Mayer et al.   CANCER RESEARCH

Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC).

(2010) M Dickler et al.   CANCER RESEARCH

Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.

(2010) HS Rugo et al.   CANCER RESEARCH

Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials.

(2010) H Roche et al.   CANCER RESEARCH

Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.

(2010) L Vahdat et al.   CANCER RESEARCH

Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.

(2010) P Conte et al.   CANCER RESEARCH

Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial.

(2010) S Johnston et al.   CANCER RESEARCH

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

(2009) Kenichi Inoue et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

(2008) V. Roy et al.   ANNALS OF ONCOLOGY

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival

(2008) Andrea C. Bafford et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

(2008) Francis Y. F. Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

(2008) Eva S. Thomas   JOURNAL OF CLINICAL ONCOLOGY

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

(2008) Martine J. Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

(2008) Kathy S. Albain et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

(2008) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY